An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
Heterogeneity in Lupus: Lessons from the Autoimmune Centers of Excellence
SAN DIEGO—The Autoimmunity Centers of Excellence (ACE) are a cooperative group funded by the National Institute of Allergy and Infectious Diseases (NIAID) that conduct basic and clinical research on autoimmune diseases.1 ACEs focus on treatment and prevention strategies that induce immune tolerance or modulate the immune system. The goal is to facilitate collaboration across clinicians…
Can SGLT2 Inhibitors Protect Our SLE Patients?
SAN DIEGO—At ACR Convergence 2023, Plenary Session 2, April M. Jorge, MD, shared data concerning the potential cardio- and renal-protective benefits of sodium-glucose co-transporter-2 inhibitors in patients with systemic lupus erythematosus and lupus nephritis.
Risks of Severe HCQ Non-Adherence
Lower HCQ Serum Levels Associated with SLE Flare, Damage & Mortality Background & Objectives: Nguyen et al. set out to assess the consequences of severe non-adherence to hydroxychloroquine (HCQ) by measuring hydroxychloroquine serum levels, risks of systemic lupus erythematosus (SLE) flares, damage and mortality over five years of follow-up. Methods: The Systemic Lupus Erythematosus International…
Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri
At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.
Belimumab vs. Oral Immunosuppressants: Infection Risk in Patients with Non-Renal SLE
Materne et al. aimed to compare the risk of infection among patients with non-renal SLE using the injectable immunosuppressant belimumab vs. an oral immunosuppressant, azathioprine, mycophenolate or methotrexate.
Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus
Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.
What Patients with Lupus Want You to Know
During a series of interviews with patients who have systemic lupus erythematosus, issues related to medication side effects, supplement use, depression and support groups arose, as well as concerns about race and activities of daily living. The interviews gave me a better understanding of what patients with lupus wish their physicians knew. I am grateful…
Break the Barrier: Understanding & Treating Neuropsychiatric Lupus
Updated research on the complexities of central nervous system (CNS) lupus, as well as its diagnosis and treatment are discussed.
Mixed Results for Rezpegaldesleukin in Patients with Active SLE
In a clinical trial, patients with active systemic lupus erythematosus (SLE) did not experience a reduction in disease activity with the addition of rezpegaldesleukin to their standard treatments. However, some patient populations did see improvements in their disease activity compared with the placebo-treated group.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 45
- Next Page »